Anteris Technologies (AVR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.2M

Revenue (quarter)

$1.0M

Revenue growth (year over year)

+63.27%

Gross profit (trailing twelve months)

$1.7M

Gross margin

74.98%

Net income (trailing twelve months)

−$102.9M

Net income (quarter)

−$28.8M

Net income growth (year over year)

−36.63%

Net margin

−4589.96%

Return on equity

−75.10%

EPS (trailing twelve months)

−$1.95

Book value per share

$2.58

P/E (trailing twelve months)

—

Price to book

2.42

Debt to assets

7.65%

Payout ratio

—

Dividend yield

—

Company profile

Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.

• Is Anteris Technologies (AVR) profitable?

  No. Anteris Technologies reported a net loss of $102.9M over the trailing twelve months.

• How much revenue does Anteris Technologies (AVR) make?

  Anteris Technologies generated $2.2M in revenue over the trailing twelve months, up 63.27% year over year.

• How do I buy stock in Anteris Technologies (AVR)?

  AVR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.